Competing interests
Cancer, Leukemia, Lymphoma, Chase Cancer, TG, NHL
LEUKEMIA, LYMPHOMA, FOX, CROSS, NHL, ONCOLOGY, CANCER
L.E.B. reports research funding from Amgen, Merck and AstraZeneca and consulting fees from Genentech, Inc., AstraZeneca, AbbVie, Bristol Myers Squibb, Kite Pharma and Nurix. A.J.O. reports being a Clinical Research Scholar of the Leukemia & Lymphoma Society; research funding from Genentech, Inc., Precision Biosciences, Genmab, Artiva, Kymera Therapeutics and Schrödinger; and consulting fees from Genmab, Blue Cross and Blue Shield of Rhode Island, Schrödinger, ADC Therapeutics and BeiGene. S.A. reports consulting fees from Ipsen, F. Hoffmann-La Roche Ltd, Genentech, Inc., Janssen, BeiGene, Gilead Sciences, Novartis and AstraZeneca. C.D. reports research funding and consulting fees from Genentech, Inc./F. Hoffmann-La Roche Ltd. M.K. reports research funding from Novartis; consultancy fees from AbbVie, AstraZeneca, Celgene/Bristol Myers Squibb, Adaptive Biotechnologies, ADC Therapeutics, BeiGene, Genentech, Inc., Syncopation and Caribou Biosciences; speakers bureau for SeaGen; and Data Monitoring Committee for Celgene and Genentech, Inc. N.G. reports research funding from TG Therapeutics, Genentech, Inc./F. Hoffmann-La Roche Ltd, Bristol Myers Squibb, Gilead Sciences, MorphoSys, AbbVie and Pharmacyclics; consulting fees from SeaGen, TG Therapeutics, AstraZeneca, Phamacyclics, Janssen, Bristol Myers Squibb, Gilead Sciences, Kite Pharma, BeiGene, Incyte corporation, Lava Therapeutics, Genentech, Inc./F. Hoffmann-La Roche Ltd, Novartis, Loxo Oncology, AbbVie, Genmab, Adaptive Biotech and ADC Therapeutics; speakers bureau for AstraZenca, Janssen, Pharmacyclics, Kite Pharma, Bristol Myers Squibb and Epizyme; and member on the board of directors/advisory committee for F. Hoffmann-La Roche Ltd NHL solutions panel. D.M. reports research funding from Genentech, Inc., ADC Therapeutics, Genmab and Karyopharm Therapeutics; speakers bureau for BeiGene; consulting fees from AstraZeneca; and advisory board member for SeaGen, ADC Therapeutics and MorphoSys. W.S. reports honoraria for advisory boards from F. Hoffmann-La Roche Ltd, Amgen, Janssen, BeiGene, Novartis, Bristol Myers Squibb, Incyte corporation and AstraZeneca and conference attendance travel support from BeiGene. S.N. reports employment with Penn State Cancer Institute; research funding from Genentech and AbbVie; and honoraria from ADC Therapeutics. A.M. reports research funding from Incyte corporation, Takeda, Forty Seven/Gilead Sciences, Juno Pharmaceuticals/Bristol Myers Squibb, Celgene/Bristol Myers Squibb, Innate Pharmaceuticals, Seattle Genetics, TG Therapeutics, Affimed, Merck, Kite Pharma/Gilead Sciences, F. Hoffmann-La Roche Ltd/Genentech, Inc. and ADC Therapeutics; consulting fees from Gilead Sciences, Seattle Genetics, Incyte corporation, MorphoSys, TG Therapeutics, Kyowa Kirin, BeiGene, F. Hoffmann-La Roche Ltd/Genentech, Inc. and ADCT; and speakers bureau for Incyte corporation/MorphoSys, BeiGene, Ipsen and Kyowa Kirin. S.K.N. reports employment with Fox Chase Cancer Center; research funding from BTG/SERB; and honoraria from Bristol Myers Squibb, BTG/SERB and ADC Therapeutics. S.D.D. reports funding from ADC Therapeutics, AstraZeneca, Bayer, BeiGene, De Novo Biopharma, Enterome, Genentech Inc., Incyte corporation, Kymera Therapeutics, Merck, Sharp & Dohme corporation, MorphoSys, Nanjing Pharmaceuticals and Viracta Therapeutics; and personal financial interests in ADC Therapeutics, AstraZeneca, BeiGene, Karyopharm Therapeutics, Kite Pharma, Incyte corporation, Numab Therapeutics, AbbVie and Genentech, Inc. K.D. reports research funding from Genmab, Janssen, F. Hoffmann-La Roche Ltd, Bristol Myers Squibb and Kite Pharma/Gilead and honoraria from Janssen. T.J. reports employment with F. Hoffmann-La Roche (China) Holding Ltd. S.P. reports employment with F. Hoffmann-La Roche Ltd (Canada). L-Y.H., J.J., H.W. and W.S.E. report employment with Genentech, Inc. I.T. reports employment with, personal financial interest in and patents/patents pending for Genentech, Inc. C.L.B. and M.C.W. report employment with and personal financial interest in Genentech, Inc. J.C.C. reports consulting fees from Kite Pharma/Gilead Sciences, Novartis, Bristol Myers Squibb, Cellectar, Adicet, Genentech, Inc., AstraZeneca, BeiGene, AbbVie, Genmab, Janssen and ADC Therapeutics; honoraria from AstraZeneca, Eli Lilly and BeiGene; research support from Merck, Janssen and AstraZeneca; and Data and Safety Monitoring Board member for Atara and the National Cancer Institute. I.S.L. has no competing interests to declare.